Course Overview


Thrombosis and Thromboembolism 2020
The State of the Art for Prevention, Evaluation, and Treatment

This special course provides a comprehensive review of the most important changes and advances impacting the care of patients who have—or are at risk for—thrombosis and thromboembolism. Updates in diagnosis, treatment and prevention are provided by world-renowned experts and Harvard Medical School’s leading clinical faculty. The curriculum includes:

  • New options for testing and diagnosis of thrombotic disorders
  • Important developments in epidemiology and pathophysiology
  • Best practices for stroke prevention (and prediction) in atrial fibrillation
  • Guidance to navigate the nuances of prescribing dual antiplatelet therapy
  • When and how to use new oral anticoagulants and interventional devices
  • Personalized medicine and lipid biology
  • Updated lipid guidelines (and controversies surrounding them)
  • Expert advice to incorporate the latest science into your practice

This program has provided practical and timely education about innovations in this field since 1987. First-time and returning attendees consistently report that the knowledge they acquire from this update changes their practice and drives better outcomes for patients.

Participants will learn state-of-the-art approaches to preventing VTE in medically ill patients; how dual anti-platelet therapy can prevent MI, stroke, and leg amputation; improved stroke prediction and prevention; and a better understanding of the link between inflammation and thrombotic illnesses.

Program Highlights

The 2020 program includes coverage of the most exciting new predictive, diagnostic and treatment options, including genetics, cardio-oncology, thrombophilia, and personalized medicine:

  • DVT/PE diagnosis, testing, parenteral and oral anticoagulants
  • Atherothrombosis: etiology, pathophysiology, therapy
  • Infertility and hypercoagulability: testing and management
  • Lipid biology, especially triglycerides and lipoprotein(a)
  • Dual antiplatelet therapy: dose, duration, reversibility
  • Stroke prevention (and prediction) in atrial fibrillation
  • Nutrition and thrombosis
  • Diabetes and metabolic syndrome and thrombosis
  • Pulmonary hypertension
  • Heart failure with preserved or reduced ejection fraction

This program is among the highest-rated Harvard Medical School CME courses.

Please note that this course is only offered once every two years, and seating is limited. To ensure a spot, early registration is strongly recommended.

Special Lecturer

Eugene Braunwald, MD
Distinguished Hersey Professor of Medicine at Harvard Medical School
Founding Chairman of the TIMI Study Group at Brigham and Women’s Hospital

For more than 30 years, Dr. Braunwald has served as Chairman of the TIMI Study Group. Science Watch listed Dr. Braunwald as the most frequently cited author in cardiology; the living Nobel Prize winners in medicine voted Dr. Braunwald “the person who has contributed the most to cardiology in recent years.”